Respiratory Diseases page image

Respiratory Diseases

Breath biomarker discovery with Breath Biopsy® could lead to non-invasive precision medicine and exacerbation detection for asthma, COPD and other chronic airway diseases.

Learn More

Podcast: American Thoracic Society

Our CEO, Billy Boyle, talks to Andrew Bishop about Breath Biopsy for respiratory diseases on the ATS podcast.

Listen Now
Anke-Hilse Matland-Van der Zee Presentation

Presentation: Anke-Hilse Matland-Van der Zee at BBCon22

Use of longitudinal breath measurements at home in chronic respiratory patients, future or fiction?

Watch Now

Webinar: Breath Biopsy for Respiratory Diseases

A research presentation that demonstrates the potential of Breath Biopsy for Respiratory Diseases.

View Webinar On-demand
Chris Brightling Presentation

Presentation: Chris Brightling at BBCon22

Breathomics for acute and chronic lung disease - getting closer to the clinic?

Go To Blog

Publication: Biomarkers of asthma phenotypes

Researchers at Liege University identified four VOCs to stratify key asthma phenotypes.

Read Publication

Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) affect over 500M people worldwide and the annual cost of treatment in the US alone is almost $60B. Although these diseases are common, diagnosis is complex as the symptoms between them overlap considerably. Further, each of these diseases can be driven by multiple subtypes with very different underlying biology and as a result choosing the right treatment is difficult.

At present, treatment relies on trial and error, where each error costs healthcare systems huge amounts of money and has a serious impact on a patient’s quality of life. A non-invasive breath test that is easy to administer and suitable for a wide range of patients would enable the right treatment to be offered sooner, and would have a profound impact on both associated costs and quality of care.

Volatile organic compounds (VOCs) on breath have repeatedly shown promise in differentiating respiratory disease subtypes. Some of these VOCs originate directly from the underlying inflammatory responses that cause these diseases, making them especially reliable indicators.

Case Studies

A detailed look at some of the research studies that are investigating biomarkers for respiratory diseases.


Our Partners

AstraZeneca Logo 577x330 Company logo GSK University of Manchester logo 3TR-logo-blog

Further Reading

Other recommended reading:

Respiratory disease infographic

Get in touch with Owlstone

Get in touch with our team to discuss how we can work together

Let's get started